Aktuellt
SENASTE
Redeye was hoping for higher sales and order intake in the third quarter. According to Heliospectra, the market is still sluggish, primarily due to the ongoing impact from Covid. The company is still very optimistic about the launch of the new biosensors in 2022, which it sees as the start of a completely new phase for Heliospectra as a company. Reported EBIT of SEK -16m is heavily impacted by the provision of SEK 5.4m to cover additional costs related to the faulty MITRA fuse. Our financial forecasts for the current year will be revised on the back of weak Q3 numbers. We will be back shortly with updated estimates and valuation.
LÄS MER
